BRII-B Surges Over 8% Intraday as Elebsiran Approaches Multiple Data Readout Milestones

Deep News

Oct 06

BRII-B (02137) surged over 8% during intraday trading. As of press time, the stock was up 4.63%, trading at HK$2.26 with a turnover of HK$25.34 million.

Guotai Junan Securities released a research report stating that BRII-B focuses on infectious diseases and central nervous system disorders, advancing a pipeline that encompasses multiple unique drug candidates. The firm noted that BRII-B is set to achieve several milestones related to Elebsiran in the near term: In the first half of 2025, the ENSURE study Cohort 4 will present 48-week end-of-treatment data at EASL 2025; ENSURE study Cohorts 1-3 will present 24-week follow-up data at EASL 2025; ENSURE study Cohort 4 will release 24-week follow-up data; and the ENRICH study will present end-of-treatment data.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1144846397"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144846397\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1144846397?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 11:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144846397","market":"hk","top_or_hot":-1,"title":"BRII-B Surges Over 8% Intraday as Elebsiran Approaches Multiple Data Readout Milestones","media":"Deep News","content":"<p>BRII-B (02137) surged over 8% during intraday trading. As of press time, the stock was up 4.63%, trading at HK$2.26 with a turnover of HK$25.34 million.</p>\n<p>Guotai Junan Securities released a research report stating that BRII-B focuses on infectious diseases and central nervous system disorders, advancing a pipeline that encompasses multiple unique drug candidates. The firm noted that BRII-B is set to achieve several milestones related to Elebsiran in the near term: In the first half of 2025, the ENSURE study Cohort 4 will present 48-week end-of-treatment data at EASL 2025; ENSURE study Cohorts 1-3 will present 24-week follow-up data at EASL 2025; ENSURE study Cohort 4 will release 24-week follow-up data; and the ENRICH study will present end-of-treatment data.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRII-B Surges Over 8% Intraday as Elebsiran Approaches Multiple Data Readout Milestones</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRII-B Surges Over 8% Intraday as Elebsiran Approaches Multiple Data Readout Milestones\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-10-06 11:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BRII-B (02137) surged over 8% during intraday trading. As of press time, the stock was up 4.63%, trading at HK$2.26 with a turnover of HK$25.34 million.</p>\n<p>Guotai Junan Securities released a research report stating that BRII-B focuses on infectious diseases and central nervous system disorders, advancing a pipeline that encompasses multiple unique drug candidates. The firm noted that BRII-B is set to achieve several milestones related to Elebsiran in the near term: In the first half of 2025, the ENSURE study Cohort 4 will present 48-week end-of-treatment data at EASL 2025; ENSURE study Cohorts 1-3 will present 24-week follow-up data at EASL 2025; ENSURE study Cohort 4 will release 24-week follow-up data; and the ENRICH study will present end-of-treatment data.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1144846397","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144846397","pubTimestamp":1759722651,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"BRII-B (02137) surged over 8% during intraday trading. As of press time, the stock was up 4.63%, trading at HK$2.26 with a turnover of HK$25.34 million. Guotai Junan Securities released a research...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","02137":"腾盛博药-B","BK1161":"生物科技","BK1587":"次新股"},"translate_title":"随着Elebsiran接近多个数据读出里程碑，BRII-B盘中飙升超过8%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02137":1},"content_text":"BRII-B (02137) surged over 8% during intraday trading. As of press time, the stock was up 4.63%, trading at HK$2.26 with a turnover of HK$25.34 million.\nGuotai Junan Securities released a research report stating that BRII-B focuses on infectious diseases and central nervous system disorders, advancing a pipeline that encompasses multiple unique drug candidates. The firm noted that BRII-B is set to achieve several milestones related to Elebsiran in the near term: In the first half of 2025, the ENSURE study Cohort 4 will present 48-week end-of-treatment data at EASL 2025; ENSURE study Cohorts 1-3 will present 24-week follow-up data at EASL 2025; ENSURE study Cohort 4 will release 24-week follow-up data; and the ENRICH study will present end-of-treatment data.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}